Evidence map›Paper›PMID 25806270›Full record

ArticleTranslational lung cancer research2013

The use of quantitative proteomics towards biomarker discovery in lung squamous cell carcinoma.

Timothy G Whitsett, Landon J Inge, Nhan L Tran

Abstract read
In one paragraph

Article in Translational lung cancer research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 88% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Timothy G WhitsettCancer and Cell Biology Division, Translational Genomics Research Institute, Phoenix, AZ, USA ;
Landon J IngeCenter for Thoracic Disease and Transplantation, Heart and Lung Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ, USA.
Nhan L TranCancer and Cell Biology Division, Translational Genomics Research Institute, Phoenix, AZ, USA ;
Translational Genomics Research Institute · US

Funding

Targeting the Fn14-Rac1 signaling pathway in invasive gliomasR01CA130940 · NCI · TRANSLATIONAL GENOMICS RESEARCH INST · PI TRAN, NHAN L · 2008 to 2012
$1.5M
NCI NIH HHS R01 CA130940
6 · The paper itself

Abstract

The high mortality rate in advanced lung cancer, due to a preponderance of tumors discovered at advanced stage, demands the discovery and clinical validation of biomarkers for diagnosing early stage disease. Quantitative proteomics technologies are capable of identifying protein biomarkers with diagnostic, prognostic, and predictive value. Recent works have demonstrated the utility in using quantitative proteomics across normal, pre-cancerous, and cancerous lesions towards the discovery of biomarkers for early stage lung cancer, as well as discovering novel mechanisms of lung carcinogenesis.

Indexed as

glutathione s-transferase pi 1 (GSTP1)isobaric tags for relative and absolute quantitation (iTRAQ)Lung squamous cell carcinomaproteomics

Identifiers

PMID25806270
PMCPMC4367630
OpenAlexW2203147601

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.